The Alopecia market growth is driven by factors like increase in the prevalence of Alopecia, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Alopecia market report also offers comprehensive insights into the Alopecia market size, share, Alopecia epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Alopecia market size growth forward.
Some of the key highlights from the Alopecia Market Insights Report:
Strategise your business goals by understanding market dynamics @ Alopecia Market Landscape
Alopecia Overview
Alopecia refers to temporary or permanent hair loss from the scalp or entire body as a result of genes, changes in hormones, medical conditions or aging, generally affecting men. Signs of Alopecia may include: gradual thinning of hair on top of head, circular or patchy bald spots on scalp, beard or eyebrows, sudden hair fall, full body hair loss and patches of stalling that spread over the scalp.
Different types of alopecia are as follows:
The treatment for alopecia depends on the cause behind the condition. Sometimes the hair loss may get better on its own and no treatment is needed. However in case of severe hair loss, medicines and hair transplant surgery are the available options.
Do you know the treatment paradigms for different countries? Download our Alopecia Market Sample Report
Recent Breakthroughs in the Alopecia Market:
FDA Approves Drug Hair Loss Treatment for Alopecia: The FDA has now approved a new drug to treat hair loss caused by alopecia. On June 23, the FDA announced approval for ritlecitinib, sold under the brand name Litfulo, a drug used to treat severe alopecia areata. The medicine has been approved for people 12 years and up. Alopecia areata is an autoimmune disease that results in hair loss. This disease affects as many as 6.7 million people in the U.S.
Alopecia Epidemiology Segmentation
DelveInsight’s Alopecia market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Alopecia historical patient pools and forecasted Alopecia patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Alopecia Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Visit for more @ Alopecia Epidemiological Insights
Alopecia Treatment Market
The Alopecia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Alopecia market trends by analyzing the impact of current Alopecia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Alopecia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Alopecia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Alopecia market in 7MM is expected to witness a major change in the study period 2019-2032.
Alopecia Emerging Drugs
KX-826: Kintor Pharma
KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of androgenetic alopecia (AGA) and acne vulgaris. For the AGA indication, on 8 September 2021, Kintor Pharma announced that the primary endpoint of the phase II clinical trial of KX-826 on adult male patients was met, as results showed good efficacy and safety profile. On 11 July 2021, Kintor Pharma announced that the Food and Drug Administration of the United States greenlighted KX-826’s phase II clinical trial for AGA to be conducted in the United States. On 31 December 2021, Kintor Pharma announced the first patient dosing in its phase III clinical trial of KX-826 in China for the treatment of male AGA patients, with 26 sites participating in this trial. On 12 November 2021, Kintor Pharma announced the first patient dosing in its phase II clinical trial of KX-826 in China for the treatment of female AGA patients. For the acne vulgaris indication, on 24 January 2022, Kintor Pharma announced the first patient dosing in its phase II clinical trial of KX-826 in China for the treatment of acne vulgaris.
Baricitinib: Reata Pharmaceuticals
Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib disrupts the activation of downstream signalling molecules and proinflammatory mediators.
Alopecia Key Companies
For more information, visit Alopecia Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Alopecia Market Report:
Key Questions Answered in the Alopecia Market Report 2032:
Table of Contents:
1 Alopecia Market Key Comprehensive Insights
2 Alopecia Market Report Introduction
3 Competitive Intelligence Analysis for Alopecia
4 Alopecia Market Analysis Overview at a Glance
5 Executive Summary of Alopecia
6 Alopecia Epidemiology and Market Methodology
7 Alopecia Epidemiology and Patient Population
8 Alopecia Patient Journey
9 Alopecia Treatment Algorithm, Alopecia Current Treatment, and Medical Practices
10 Key Endpoints in Alopecia Clinical Trials
11 Alopecia Marketed Therapies
12 Alopecia Emerging Therapies
13 Alopecia: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Alopecia
16 Alopecia Market Key Opinion Leaders Reviews
18 Alopecia Market Drivers
19 Alopecia Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Alopecia Epidemiology 2032
DelveInsight’s “Alopecia – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Alopecia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Alopecia Pipeline 2023
“Alopecia Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Alopecia market. A detailed picture of the Alopecia pipeline landscape is provided, which includes the disease overview and Alopecia treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +91-9650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
